3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
7
Non-Muscle Invasive Bladder Neoplasms
5
Carcinoma, Transitional Cell
2
Anus Neoplasms
2
Urothelial Carcinoma of the Bladder
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Rectal Neoplasms
1
Peritoneal Neoplasms
1
Peritoneal Diseases
1
Neoplasms by Site
1
Neoplasms
1
Male Urogenital Diseases
1
HIV Infections
1
Female Urogenital Diseases
1
Colorectal Neoplasms
1
Appendiceal Neoplasms
1
Anal Canal Carcinoma
1
Interventions
pembrolizumab
2
enfortumab vedotin
2
Gemcitabine
2
testosterone 17 beta-cypionate
1
temsirolimus
1
Valproic Acid
1
Testosterone Propionate
1
Standard of Care
1
Sirolimus
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Mitomycin
1
Methyltestosterone
1
Immunoglobulin G
1
Fluorouracil
1
Disulfides
1
Cisplatin
1
Cetuximab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Mitomycin
×
30 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled